IBA Molecular to Buy Mallinckrodt's Nuclear Medicine Business

$690 million deal.

 
Radiopharmacy vendor IBA Molecular has signed an agreement to acquire Mallinckrodt’s nuclear imaging business in a deal valued at $690 million. Mallinckrodt’s business produces the radioisotope molybdenum-99, from which technetium-99m is derived. Technetium-99m is used in approximately 80% of all nuclear medicine procedures worldwide, and approximately two-thirds of revenues from Mallinckrodt’s nuclear imaging business originate in the U.S.

Read the full artcile here.